397 reports of this reaction
2.7% of all PEGVALIASE PQPZ reports
#8 most reported adverse reaction
INJECTION SITE PAIN is the #8 most commonly reported adverse reaction for PEGVALIASE PQPZ, manufactured by BioMarin Pharmaceutical Inc.. There are 397 FDA adverse event reports linking PEGVALIASE PQPZ to INJECTION SITE PAIN. This represents approximately 2.7% of all 14,737 adverse event reports for this drug.
Patients taking PEGVALIASE PQPZ who experience injection site pain should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
INJECTION SITE PAIN is a less commonly reported adverse event for PEGVALIASE PQPZ, but still significant enough to appear in the safety profile.
In addition to injection site pain, the following adverse reactions have been reported for PEGVALIASE PQPZ:
The following drugs have also been linked to injection site pain in FDA adverse event reports:
INJECTION SITE PAIN has been reported as an adverse event in 397 FDA reports for PEGVALIASE PQPZ. This does not prove causation, but indicates an association observed in post-market surveillance data.
INJECTION SITE PAIN accounts for approximately 2.7% of all adverse event reports for PEGVALIASE PQPZ, making it a notable side effect.
If you experience injection site pain while taking PEGVALIASE PQPZ, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.